HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
04 2019
Historique:
received: 07 02 2019
accepted: 26 02 2019
pubmed: 6 3 2019
medline: 4 12 2019
entrez: 6 3 2019
Statut: ppublish

Résumé

A cure for HIV-1 remains unattainable as only one case has been reported, a decade ago

Identifiants

pubmed: 30836379
doi: 10.1038/s41586-019-1027-4
pii: 10.1038/s41586-019-1027-4
pmc: PMC7275870
mid: EMS86513
doi:

Substances chimiques

CCR5 protein, human 0
CXCR4 protein, human 0
HIV Antibodies 0
Receptors, CCR5 0
Receptors, CXCR4 0
gag Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

244-248

Subventions

Organisme : Medical Research Council
ID : MR/L006588/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P011233/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M008614/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R008698/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M008614/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N02043X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 108082
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Références

Hütter, G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692–698 (2009).
doi: 10.1056/NEJMoa0802905
Allers, K. et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 117, 2791–2799 (2011).
doi: 10.1182/blood-2010-09-309591
UNAIDS. UNAIDS Data 2017 http://www.unaids.org/en/resources/documents/2017/20170720_Data_book_2017 (2017).
Gupta, R. K. et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect. Dis. 18, 346–355 (2018).
doi: 10.1016/S1473-3099(17)30702-8
The TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect. Dis. 16, 565–575 (2016).
doi: 10.1016/S1473-3099(15)00536-8
Barth, R. E., van der Loeff, M. F., Schuurman, R., Hoepelman, A. I. & Wensing, A. M. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect. Dis. 10, 155–166 (2010).
doi: 10.1016/S1473-3099(09)70328-7
Avert. Funding for HIV and AIDS https://www.avert.org/professionals/hiv-around-world/global-response/funding (2017).
Simmons, G. et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70, 8355–8360 (1996).
pubmed: 8970955 pmcid: 190923
Kordelas, L. et al. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N. Engl. J. Med. 371, 880–882 (2014).
doi: 10.1056/NEJMc1405805
Verheyen, J. et al. Rapid rebound of a preexisting CXCR4-tropic human immunodeficiency virus variant after allogeneic transplantation with CCR5 Δ32 homozygous stem cells. Clin. Infect. Dis. 64, 684–687 (2019).
doi: 10.1093/cid/ciy565
Symons, J. et al. Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient. Clin. Infect. Dis. 59, 596–600 (2014).
doi: 10.1093/cid/ciu284
Henrich, T. J. et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161, 319–327 (2014).
doi: 10.7326/M14-1027
Cummins, N. W. et al. Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: a case study. PLoS Med. 14, e1002461 (2017).
doi: 10.1371/journal.pmed.1002461
Bosman, K. J. et al. Development of sensitive ddPCR assays to reliably quantify the proviral DNA reservoir in all common circulating HIV subtypes and recombinant forms. J. Int. AIDS Soc. 21, e25185 (2018).
doi: 10.1002/jia2.25185
Yukl, S. A. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 9, e1003347 (2013).
doi: 10.1371/journal.ppat.1003347
Ritchie, A. V. et al. Performance evaluation of the point-of-care SAMBA I and II HIV-1 Qual whole blood tests. J. Virol. Methods 237, 143–149 (2016).
doi: 10.1016/j.jviromet.2016.08.017
Laird, G. M. et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 9, e1003398 (2013).
doi: 10.1371/journal.ppat.1003398
Fun, A., Mok, H. P., Wills, M. R. & Lever, A. M. A highly reproducible quantitative viral outgrowth assay for the measurement of the replication-competent latent HIV-1 reservoir. Sci. Rep. 7, 43231 (2017).
doi: 10.1038/srep43231
Jensen, M. A., Coetzer, M., van ’t Wout, A. B., Morris, L. & Mullins, J. I. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J. Virol. 80, 4698–4704 (2006).
doi: 10.1128/JVI.80.10.4698-4704.2006
Lengauer, T., Sander, O., Sierra, S., Thielen, A. & Kaiser, R. Bioinformatics prediction of HIV coreceptor usage. Nat. Biotechnol. 25, 1407–1410 (2007).
doi: 10.1038/nbt1371
Smith, N. M. et al. Proof-of-principle for immune control of global HIV-1 reactivation in vivo. Clin. Infect. Dis. 61, 120–128 (2015).
doi: 10.1093/cid/civ219
Watters, S. A. et al. Sequential CCR5-tropic HIV-1 reactivation from distinct cellular reservoirs following perturbation of elite control. PLoS ONE 11, e0158854 (2016).
doi: 10.1371/journal.pone.0158854
Salgado, M. et al. Mechanisms that contribute to a profound reduction of the HIV-1 reservoir after allogeneic stem cell transplant. Ann. Intern. Med. 169, 674–683 (2018).
doi: 10.7326/M18-0759
Hamilton, B. K. et al. Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hematopoietic cell transplantation. Bone Marrow Transplant. 48, 1578–1580 (2013).
doi: 10.1038/bmt.2013.89
Duarte, R. F. et al. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. Lancet HIV 2, e236–e242 (2015).
doi: 10.1016/S2352-3018(15)00083-1
Pavlů, J. et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematol. Oncol. 29, 75–80 (2011).
doi: 10.1002/hon.956
Bronnimann, M. P., Skinner, P. J. & Connick, E. The B-cell follicle in HIV infection: barrier to a cure. Front. Immunol. 9, 20 (2018).
doi: 10.3389/fimmu.2018.00020
Symons, J. et al. Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice. Clin. Microbiol. Infect. 18, 606-612 (2012).
doi: 10.1111/j.1469-0691.2011.03631.x
Edgar, R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792–1797 (2004).
doi: 10.1093/nar/gkh340
Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30, 1312–1313 (2014).
doi: 10.1093/bioinformatics/btu033
Amendola, A. Standardization and performance evaluation of “modified” and “ultrasensitive” versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia. J. Clin. Virol. 42, 17–22 (2011).
doi: 10.1016/j.jcv.2011.04.012

Auteurs

Ravindra K Gupta (RK)

Division of Infection and Immunity, UCL, London, UK. rkg20@cam.ac.uk.
Department of Infection, UCLH, London, UK. rkg20@cam.ac.uk.
Mortimer Market Centre, Department of HIV, CNWL NHS Trust, London, UK. rkg20@cam.ac.uk.
Department of Medicine, University of Cambridge, Cambridge, UK. rkg20@cam.ac.uk.
Africa Health Research Institute, Durban, South Africa. rkg20@cam.ac.uk.

Sultan Abdul-Jawad (S)

Division of Infection and Immunity, UCL, London, UK.

Laura E McCoy (LE)

Division of Infection and Immunity, UCL, London, UK.

Hoi Ping Mok (HP)

Department of Medicine, University of Cambridge, Cambridge, UK.

Dimitra Peppa (D)

Mortimer Market Centre, Department of HIV, CNWL NHS Trust, London, UK.
Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Maria Salgado (M)

IrsiCaixa AIDS Research Institute, Badalona, Spain.

Javier Martinez-Picado (J)

IrsiCaixa AIDS Research Institute, Badalona, Spain.
University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain.
Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.

Monique Nijhuis (M)

Translational Virology, Department of Medical Microbiology, University Medical Center, Utrecht, The Netherlands.

Annemarie M J Wensing (AMJ)

Translational Virology, Department of Medical Microbiology, University Medical Center, Utrecht, The Netherlands.

Helen Lee (H)

Department of Haematology, University of Cambridge, Cambridge, UK.

Paul Grant (P)

Department of Virology, UCLH, London, UK.

Eleni Nastouli (E)

Department of Virology, UCLH, London, UK.

Jonathan Lambert (J)

Department of Haematology, UCLH, London, UK.

Matthew Pace (M)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Fanny Salasc (F)

Department of Medicine, University of Cambridge, Cambridge, UK.

Christopher Monit (C)

Division of Infection and Immunity, UCL, London, UK.

Andrew J Innes (AJ)

Department of Clinical Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Imperial College London, London, UK.

Luke Muir (L)

Division of Infection and Immunity, UCL, London, UK.

Laura Waters (L)

Mortimer Market Centre, Department of HIV, CNWL NHS Trust, London, UK.

John Frater (J)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, Oxford, UK.

Andrew M L Lever (AML)

Department of Medicine, University of Cambridge, Cambridge, UK.
Department of Medicine, National University of Singapore, Singapore, Singapore.

Simon G Edwards (SG)

Mortimer Market Centre, Department of HIV, CNWL NHS Trust, London, UK.

Ian H Gabriel (IH)

Department of Clinical Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Imperial College London, London, UK.
Department of Haematology, Chelsea and Westminster Hospitals Foundation NHS Trust, London, UK.

Eduardo Olavarria (E)

Department of Clinical Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH